Company intelligence / Profile preview

Cerulean Scientific

Durham, North Carolina, United Statesceruleanscientific.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cerulean’s surface coating platform has demonstrated increased survival time, improved clinical outcomes, and significantly reduced cell attachment in animal studies of ventricular catheters. In vascular access models, their hemodialysis catheter showed no clogging versus standard devices. The company holds 23 issued patents with 16 pending and has completed multiple large animal studies. No human clinical trial data is yet available; regulatory submissions are planned for 2026.

Therapeutic areas: NephrologyNeurology
Modalities: DeviceSurface coating technology (Cerulean Surface technology)
Industry: Implantable Medical Devices

Partnerships

Harvard's Wyss Institute/VESA Institute (technology licensed from here)

Beyond the preview

Go deeper on Cerulean Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerulean Scientific.

Explore the full profile